Prevest Denpro LtdQ2 FY25

Prevest Denpro Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 407P/E: 20.3Market Cap: ₹458 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Prevest Denpro Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Prevest Denpro Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Prevest Denpro Ltd — get its next earnings analysis in your feed

Margin guidance

No information is provided regarding the same in the latest conference call.

Order book

No information is provided regarding the same in the latest conference call.

How does Prevest Denpro Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature
ThisPrevest Denpro Ltd

How does Prevest Denpro Ltd rank in Healthcare Equipment & Supplies?

Compare Prevest Denpro Ltd against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Others in Healthcare Equipment & Supplies this season

  • QMS Medical (Q1 FY27)

    Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…

  • Laxmi Dental (Q1 FY27)

    PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…

  • Tarsons Products (Q2 FY26)

    Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…

  • Vaidya Sane (Q2 FY26)

    Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →